Clinical trials: Recurrent Solid Neoplasm
Chronic Myeloproliferative Disorders, Fatigue
American Ginseng in Treating Patients With Fatigue Caused by Cancer
RATIONALE: American ginseng may reduce fatigue in patients with cancer. It is not yet known whether American ginseng is more effective than a placebo in treating cancer-related fatigue.
- Conditions
- Chronic Myeloproliferative Disorders, Fatigue, Leukemia, Lymphoma
- Trial name
- NCT00719563
- Testing
- American ginseng
- Where
- 326 sites in United States
- Volunteers
- 364 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Type and Grade of Toxicities, Demographic and Background Characteristics, Advanced, Metastatic, Recurrent Adenocarcinoma and Malignant Solid Neoplasm
Labyrinthin Vaccination in Veterans With Lung Adenocarcinoma
This phase 2 trial tests the safety and effectiveness of a cancer vaccine called LabVax 3(22)-23 and GM-CSF in combination with pembrolizumab in treating adenocarcinoma that has spread to other places in the body (advanced…
- Trial name
- NCT07859592
- Testing
- LabVax 3(22)-23 and GM-CSF (adjuvant) in combination with pembrolizumab
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- VA Office of Research and Development
Breast Cancer, Lung Cancer
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
RATIONALE: Gathering information about how often osteonecrosis of the jaw occurs in patients receiving zoledronic acid for bone metastases may help doctors learn more about the disease and provide the best follow-up care.
- Conditions
- Breast Cancer, Lung Cancer, Metastatic Cancer, Multiple Myeloma
- Trial name
- NCT00874211
- Testing
- assessment of therapy complications
- Where
- 453 sites in United States, Mexico and 1 more
- Volunteers
- 3,571 people
- Sponsor
- SWOG Cancer Research Network
Refractory Cancer, Recurrent Cancer
IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors
The goal of this clinical trial is to evaluate the safety, tolerability and anti-tumor activity of IMA402 in patients with recurrent and/or refractory solid tumors.
- Conditions
- Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult, Cancer
- Trial name
- NCT05958121
- Testing
- IMA402, IMA402 and checkpoint inhibitor, IMA402 and chemotherapy
- Where
- 29 sites in Germany, Netherlands
- Volunteers
- 400 people
- Sponsor
- Immatics Biotechnologies GmbH
Leukemia, Lymphoma
Interferon Alfa in Treating Children With HIV-Related Cancer
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. PURPOSE: Phase II trial to study the effectiveness of interferon alfa in treating children with an HIV-related cancer including leukemia, non-Hodgkin's…
- Conditions
- Leukemia, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00002621
- Testing
- recombinant interferon alfa
- Where
- 10 sites in United States, Canada and 2 more
- Volunteers
- 8 people
- Sponsor
- Children's Oncology Group
Ependymoma, Ewing Sarcoma
A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer
The purpose of this study is to first, in Part A, assess the safety, tolerability and drug levels of Bempegaldesleukin (BEMPEG) in combination with nivolumab and then, in Part B, to estimate the preliminary efficacy in children…
- Conditions
- Ependymoma, Ewing Sarcoma, High-grade Glioma, Leukemia and Lymphoma
- Trial name
- PIVOT IO 020 (NCT04730349)
- Testing
- Nivolumab, NKTR-214
- Where
- 18 sites in United States, Australia and 4 more
- Volunteers
- 15 people
- Sponsor
- Bristol-Myers Squibb
Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
Liposomal Doxorubicin and PSC 833 in Treating Patients With AIDS-Related Kaposi's Sarcoma or Other Advanced Cancers
The rationale for conducting this study lies in the premise that if indeed the reason for a limited response of Kaposi's sarcoma lesions and other advanced malignancies to chemotherapy is attributable to a high expression of…
- Trial name
- NCT00003207
- Testing
- pegylated liposomal doxorubicin hydrochloride, PSC 833
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Washington University School of Medicine
Non-colorectal Cancer, Pancreatic Cancer
Maytansinoid DM4-Conjugated Humanized Monoclonal Antibody huC242 in Treating Patients With Solid Tumors
RATIONALE: Monoclonal antibodies, such as maytansinoid DM4-conjugated humanized monoclonal antibody huC242, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00352131
- Testing
- HuC242-DM4
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- ImmunoGen, Inc.
Childhood Langerhans Cell Histiocytosis, Fanconi Anemia
Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases
RATIONALE: Umbilical cord blood transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy.
- Conditions
- Childhood Langerhans Cell Histiocytosis, Fanconi Anemia, Leukemia, Lymphoma
- Trial name
- NCT00084695
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Milton S. Hershey Medical Center
Relapsed / Refractory Solid Tumor
A Clinical Study of CHT101 in CD70-Positive Advanced Solid Tumors
Evaluate the safety and efficacy of CD70-targeting UCAR-T cells in the treatment of CD70-positive advanced solid tumors.
- Trial name
- NCT06730659
- Testing
- CHT101
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Rhabdoid Tumor, Atypical Teratoid/Rhabdoid Tumor
A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT
This trial is evaluating the anti-tumor activity and side effects of panobinostat in treating patients with osteosarcoma, malignant rhabdoid tumor/atypical teratoid rhabdoid tumor (MRT/ATRT), and neuroblastoma.
- Conditions
- Rhabdoid Tumor, Atypical Teratoid/Rhabdoid Tumor, Malignant Rhabdoid Tumor, Recurrent Brain Tumor, Childhood
- Trial name
- NORTH (NCT04897880)
- Testing
- Panobinostat
- Where
- 11 sites in United States, Australia and 1 more
- Volunteers
- 25 people
- Sponsor
- Australian & New Zealand Children's Haematology/Oncology Group
Refractory Cancer, CNS Tumors
A Study of Avutometinib for People With Solid Tumor Cancers
The purpose of this study is to find out whether avutometinib is a safe treatment for advanced or recurrent solid tumor cancers in children and young adults.
- Conditions
- Refractory Cancer, CNS Tumors, CNS Tumor, Adult, CNS Tumor, Childhood
- Trial name
- NCT06104488
- Testing
- Avutometinib
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cancer, Pediatric Cancer
Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid Tumors
The primary purpose of this study is to determine the pediatric maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), and to evaluate the safety and tolerability of zanzalintinib.
- Trial name
- NCT07773454
- Testing
- Zanzalintinib
- Volunteers
- 18 people
- Sponsor
- Exelixis
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer
RATIONALE: Giving an infusion of natural killer cells from a donor after a donor stem cell transplant may help kill any remaining cancer cells after the transplant.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00823524
- Testing
- donor natural killer cell infusion
- Where
- South Korea
- Volunteers
- 47 people
- Sponsor
- Asan Medical Center
Lymphoma, Prostate Cancer
AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma
RATIONALE: Monoclonal antibodies, such as AMG-479, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Conditions
- Lymphoma, Prostate Cancer, Sarcoma, Small Intestine Cancer
- Trial name
- NCT00562380
- Testing
- ganitumab, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Amgen
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
This phase I/II clinical trial is studying the side effects and best dose of gamma-secretase inhibitor RO4929097 and to see how well it works in treating young patients with relapsed or refractory solid tumors, CNS tumors…
- Conditions
- Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Germinoma, Childhood Central Nervous System Mixed Germ Cell Tumor
- Trial name
- NCT01088763
- Testing
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, diagnostic laboratory biomarker analysis, pharmacological study
- Where
- 12 sites in United States, Canada
- Volunteers
- 129 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumors, Recurrent or Refractory Medulloblastoma
A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors
This first-in-human dose-escalation study is to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of LEQ506 given orally on a daily dosing schedule in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumors, Recurrent or Refractory Medulloblastoma, Locally Advanced or Metastatic Basal Cell Carcinoma
- Trial name
- NCT01106508
- Testing
- LEQ506
- Where
- 5 sites in United States, Netherlands and 2 more
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Stage IV or Recurrent Carcinoma or Sarcoma
Definitive Therapy for Oligometastatic Solid Malignancies
Patients with metastatic cancer are usually treated with systemic therapy (treating the entire body) with the assumption that any localized treatment of clinically apparent metastases would not impact survival.
- Trial name
- NCT01898962
- Testing
- Complete Surgical Removal, Stereotactic Radiosurgery, Ablative external beam radiation dose
- Where
- 4 sites in United States
- Volunteers
- 110 people
- Sponsor
- Rocky Mountain Cancer Centers
Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma, Biomarker-positive EGFR/HER2- Expressing HNSCC
EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC
This example Phase 1/2 protocol evaluates allogeneic EGFR/HER2 dual-target CAR-NK cells in adults with recurrent or metastatic HNSCC whose tumors meet protocol-defined co-expression criteria for EGFR and HER2/ERBB2.
- Trial name
- DUAL-HN (NCT07617805)
- Testing
- EGFR/HER2 Dual-Target CAR-NK Cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Beijing Biotech
CNS Tumor, Solid Tumor
Pedi-STAR: Surface Target Antibody-drug Conjugate (ADC) Antigen Expression in Relapsed/Refractory Pediatric Solid and CNS Tumors
This study is looking to learn whether a tumor testing approach can feasibly measure antibody-drug conjugate (ADC) target proteins in children and young adults with relapsed or refractory solid tumors or central nervous system…
- Conditions
- CNS Tumor, Solid Tumor, Relapsed Cancer, Refractory Cancer
- Trial name
- NCT07793994
- Testing
- Bulk RNA Sequencing, Immunohistochemistry (IHC)
- Where
- 2 sites in United States
- Volunteers
- 130 people
- Sponsor
- Dana-Farber Cancer Institute